Background
Materials and methods
Patients
Statistics
Results
Distribution of GD types
GD1 | GD2 | GD3 | Unclassified | |
---|---|---|---|---|
Number of cases (n = 27) | 9 (33%) | 3 (11%) | 14 (52%) | 1 (4%) |
Sex | ||||
Male | 5 (56%) | 1 (33%) | 8 (57%) | 1 (100%) |
Female | 4 (44%) | 2 (67%) | 6 (43%) | 0 (0%) |
Molecular diagnosis | ||||
p.Leu483Pro/p.Leu483Pro | – | – | 11 (79%) | – |
p.Leu483Pro/p.Val414Leu | 4 (44%) | – | – | – |
p.Leu483Pro/p.Asp448His | – | – | 2 (14%) | – |
p.Leu483Pro/RecNciI† | – | 1 (33%) | 1 (7%) | – |
p.Leu483Pro/p.Asn227Ser | 1 (11%) | – | – | – |
p.Leu483Pro/p.Asn409Ser | 1 (11%) | – | – | – |
p.Leu483Pro/p.Phe252Ile | 1 (11%) | – | – | – |
p.Leu483Pro/p.Arg170His | 1 (11%) | – | – | – |
p.Leu483Pro/p.Arg159Trp | – | – | – | 1 (100%) |
RecNciI/p.Asp448His | – | 1 (33%) | – | – |
RecNciI/p.Arg159Trp | 1 (11%) | – | – | – |
p.Phe252Val/p.328Alafs*12 | – | 1 (33%) | – | – |
Category of diagnosis | ||||
Clinical (n = 21) | 8 (38%) | 1 (5%) | 12 (57%) | – |
Newborn screening (n = 6) | 1 (17%) | 2 (33%) | 2 (33%) | 1 (17%) |
Initial presentation | ||||
Hepatosplenomegaly | 8 (89%) | 2 (67%) | 12 (86%) | 0 (0%) |
Anemia/thrombocytopenia | 7 (78%) | 1 (33%) | 12 (86%) | 0 (0%) |
Bone pain/bone crisis | 3 (33%) | 0 (0%) | 2 (14%) | 0 (0%) |
Abnormal eye movements | 0 (0%) | 2 (67%) | 1 (7%) | 0 (0%) |
Poor feeding | 0 (0%) | 2 (67%) | 0 (0%) | 0 (0%) |
Ichthyosis | 0 (0%) | 1 (33%) | 0 (0%) | 0 (0%) |
Median [IQR] age at diagnosis, years | ||||
Clinical diagnosis | 24.41 [3.72–35.65] | 0.92 | 2.52 [1.87–8.70] | – |
Newborn screening | 0.08 | 0.14 | 0.26 | 0.08 |
Median [IQR] age at ERT, years | ||||
Clinical diagnosis | 29.44 [3.68–42.91] | –‡ | 3.17 [2–16.75] | – |
Newborn screening | 2.83 | 0.56 | 0.66 | – |
Treatment§ | ||||
ERT | 9 (100%) | 1 (33%) | 14 (100%) | – |
SRT | 1 (11%) | 0 (0%) | 6 (43%) | – |
Ambroxol | 1 (11%) | 0 (0%) | 5 (36%) | – |
HSCT | 0 (0%) | 1 (33%) | 0 (0%) | – |
Splenectomy | 4 (44%) | 0 (0%) | 2 (14%) | – |
5-year survival rate | 100% | 0% | 100% | 0% |
Clinical | NBS | p value | |
---|---|---|---|
Number of patients (n = 27) | 21 | 6 | |
Subtype | |||
GD1 | 8 (38%) | 1 (17%) | 0.182 |
GD2 | 1 (5%) | 2 (33%) | 0.054 |
GD3 | 12 (57%) | 2 (33%) | 0.542 |
Molecular diagnosis | |||
p.Leu483Pro/p.Leu483Pro | 10 (48%) | 1 (17%) | 0.182 |
p.Leu483Pro/p.Val414Leu | 4 (19%) | – | 0.256 |
p.Leu483Pro/p.Asp448His | 2 (10%) | – | 0.441 |
p.Leu483Pro/RecNciI† | – | 2 (33%) | 0.007** |
p.Leu483Pro/p.Asn227Ser | 1 (5%) | – | 0.593 |
p.Leu483Pro/p.Asn409Ser | 1 (5%) | – | 0.593 |
p.Leu483Pro/p.Phe252Ile | 1 (5%) | – | 0.593 |
p.Leu483Pro/p.Arg170His | – | 1 (17%) | 0.061 |
p.Leu483Pro/p.Arg159Trp | 1 (5%) | 1 (17%) | 0.335 |
RecNciI/p.Asp448His | 1 (5%) | – | 0.593 |
RecNciI/p.Arg159Trp | – | – | 1.000 |
p.Phe252Val/p.328Alafs*12 | – | 1 (17%) | 0.061 |
Initial presentation | |||
Hepatosplenomegaly | 21 (100%) | 1 (17%) | < 0.001*** |
Anemia/thrombocytopenia | 20 (95%) | 1 (17%) | < 0.001*** |
Bone pain/bone crisis | 5 (24%) | 0 (0%) | 0.194 |
Abnormal eye movements | 2 (10%) | 1 (17%) | 0.630 |
Poor feeding | 1 (5%) | 1 (17%) | 0.335 |
Ichthyosis | 0 (0%) | 1 (17%) | 0.061 |
Median [IQR] age at diagnosis, years | 3.5 [2–24.41] | 0.05 [0.05–0.20] | < 0.001*** |
Median [IQR] age at symptom onset, years | 3.5 [2–24.41] | 0.5 [0.05–1.37] | 0.002** |
Median [IQR] age at ERT, years | 4.98 [2.18–30.03] | 0.86 [0.20–2.43] | 0.013* |
5-year survival | 20 (95%) | 3 (50%) | 0.007** |
Age of diagnosis decreased with years
Initial phenotypes: clinical cases versus NBS cases
Management
Outcomes
ID | Genotype | Age of onset of symptoms | Oculomotor apraxia | Seizure | Intellectual disability | Lymphadenopathy | Kyphosis |
---|---|---|---|---|---|---|---|
1 | p.Leu483Pro/p.Leu483Pro | 2.42 | + | + | – | + | + |
2 | p.Leu483Pro/p.Leu483Pro | 9.50 | + | + | – | – | – |
3 | p.Leu483Pro/p.Leu483Pro | 2.62 | – | – | – | + | – |
4 | p.Leu483Pro/p.Leu483Pro | 0.88 | – | – | – | + | + |
5 | p.Leu483Pro/p.Leu483Pro | 1.18 | + | + | + | + | + |
6 | p.Leu483Pro/p.Leu483Pro | 1.83 | – | – | – | + | + |
7 | p.Leu483Pro/p.Leu483Pro | 3.50 | + | – | – | + | – |
8 | p.Leu483Pro/p.Leu483Pro | 1.23 | + | + | – | + | – |
9 | p.Leu483Pro/p.Leu483Pro | 2.00 | – | – | + | – | + |
10 | p.Leu483Pro/p.Leu483Pro | 18 | + | – | – | – | – |
11 | p.Leu483Pro/p.Leu483Pro | 2 | + | – | – | – | + |
12 | p.Leu483Pro/p.Asp448His | 31.7 | + | – | – | – | – |
13 | p.Leu483Pro/p.Asp448His | 6.29 | + | – | – | – | + |
14 | p.Leu483Pro/RecNciI† | 0.10 | + | – | + | – | – |